BioCurex, Inc.(fka BOCX)

[HALF FULL GLASS]

Opportunity, I like this part!

January/February 2008
A new biomarker may have the potential to help mammography identify malignant versus benign breast lesions. RECAF (Receptor of Alpha Fetoprotein) has been found in over 90 percent of the breast cancers studied to date, according to BioCurex. The marker is present on the surface and within cancer cells, as well as in the blood of cancer patients.

According to the researcher who discovered the RECAF marker, Ricardo Moro-Vidal, M.D., CEO and president, the company is gearing up to begin a clinical trial with a leading institution to determine if a blood test can help radiologists better anticipate if a lesion is benign or malignant. In a malignant tumor, the levels of RECAF circulation within the blood increase. “If we can obtain 93 percent sensitivity and specificity, then we can potentially help reduce the number of false positives that lead to unnecessary breast biopsies,” he said. <

Being that most of this article is about Siemens...I wonder if this is the leading institution? Or maybe Abbott??